Results from a rosuvastatin historical cohort study in more than 45000 Dutch statin users, a PHARMO study

Pharmacoepidemiology and Drug Safety

Volumn 15, Issue 7, 2006, Pages 435-443

  Goettsch, W G ^a   Heintjes, E M ^a   Kastelein, J J P ^b   Rabelink, T J ^c   Johansson, Saga ^d,e   Herings, R M C ^a,f  

^a PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c LEIDEN UNIVERSITY   (Netherlands)

^d ASTRAZENECA R AND D   (Sweden)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Acute renal failure; Historical cohort study; Myopathy; Rhabdomyolysis; Rosuvastatin; Statin

Indexed keywords

ALANINE AMINOTRANSFERASE; ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; THROMBIN;

ACUTE KIDNEY FAILURE; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD CLOTTING DISORDER; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG USE; ENZYME DEFECT; FACTUAL DATABASE; FEMALE; HEPATIC COMA; HEPATIC ENCEPHALOPATHY; HISTORICAL RESEARCH; HOSPITALIZATION; HUMAN; INCIDENCE; JAUNDICE; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MYOGLOBINURIA; MYOPATHY; NETHERLANDS; PRESCRIPTION; PRIORITY JOURNAL; PROTEIN DEFECT; RHABDOMYOLYSIS; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA; VALIDATION PROCESS;

ACUTE KIDNEY INJURY; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY FAILURE, ACUTE; LIVER; MALE; MIDDLE AGED; MUSCULAR DISEASES; PYRIMIDINES; RHABDOMYOLYSIS; SULFONAMIDES;

EID: 33746616421     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1278     Document Type: Article

References (30)

1. Bolego C, Baetta R, Bellosta S, Corsini A, Paoletti R. Safety considerations for statins. Curr Opin Lipidol 2002; 13(6): 637-644.
2. Farmer JA. Learning from the cerivastatin experience. Lancet; 2001; 358(9291): 1383-1385.
3. Black DM. A general assessment of the safety of HMG CoA reductase inhibitors (statins). Curr Atheroscler Rep 2002; 4(1): 34-41.
4. Ucar M, Mjorndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 2000; 22(6): 441-457.
5. Tolman KG. The liver and lovastatin. Am J Cardiol 2002; 89(12): 1374-1380.
6. Lin JC, Ito MK, Stolley SN, Morreale AP, Marcus DB. The effect of converting from pravastatin to simvastatin on the pharmacodynamics of warfarin. J Clin Pharmacol 1999; 39(1): 86-90.
7. Simonson SG, Martin PD, Mitchell PD, Lasseter K, Gibson G, Schneck DW. Effect of rosuvastatin on warfarin pharmacodynamics and pharmacokinetics. J Clin Pharmacol 2005; 45(8): 927-934.
8. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002; 346(7): 539-540.
9. Heuer T, Gerards H, Pauw M, Gabbert HE, Reis HE. [Toxic liver damage caused by HMG-CoA reductase inhibitor]. Med Klin (Munich) 2000; 95(11): 642-644.
10. Punthakee Z, Scully LJ, Guindi MM, Ooi TC. Liver fibrosis attributed to lipid lowering medications: two cases. J Intern Med 2001; 250(3): 249-254.
11. Iliadis EA, Konwinski MF. Lovastatin during warfarin therapy resulting in bleeding. Pa Med 1995; 98(12): 31.
12. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000; 101(2): 207-213.
13. Chang JT, Staffa JA, Parks M, Green L. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Safe 2004; 13(7): 417-426.
14. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003; 289(13): 1681-1690.
15. Gaist D, Rodriguez LA, Huerta C, Hallas J, Sindrup SH. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology 2001; 12(5): 565-569.
16. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004; 292(21): 2585-2590.
17. Pasternak RC, Smith SC, Jr., Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Stroke 2002; 33(9): 2337-2341.
18. Wolfe SM. Dangers of rosuvastatin identified before and after FDA approval. Lancet 2004; 363(9427): 2189-2190.
19. Cohen JS. Should rosuvastatin be withdrawn from the market? Lancet 2004; 364(9445): 1579 (discussion 80).
20. Florentinus SR, Heerdink ER, Klungel OH, de Boer A. Should rosuvastatin be withdrawn from the market? Lancet 2004; 364(9445): 1577 (author reply 8-9).
21. Kastelein JJ. Should rosuvastatin be withdrawn from the market? Lancet 2004; 364(9445): 1577-1578 (author reply 8-9).
22. Olsson AG. Safety and efficacy of rosuvastatin. Lancet 2004; 364(9429): 135.
23. Alsheikh-Ali AA, Ambrose MS, Kuvin JT, Karas RH. The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation 2005; 111(23): 3051-3057.
24. Breslow NE, Day NE. The Design and Analysis of Cohort Studies. IARC: Lyon, 1987.
25. Shepherd J, Hunninghake DB, Stein EA, et al. Safety of rosuvastatin. Am J Cardiol 2004; 94(7): 882-888.
26. Brewer HB, Jr. Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams. Am J Cardiol 2003; 92(4B): 23K-29K.
27. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366(9493): 1267-1278.
28. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350(15): 1495-1504.
29. Larosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352(14): 1425-1435.
30. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL Study: A randomized controlled trial. JAMA 2005; 294(19): 2437-2445.